Case Study: Biosimilar Anti TNFalpha (Adalimumab) Analysis of Fc Effector Functions

BMC Proceedings - United Kingdom
doi 10.1186/1753-6561-7-s6-p30
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Budget Impact Analysis of Adalimumab Biosimilar: The Italian Context

AboutOpen
2019English

Serum IgA Fc Effector Functions in Infectious Disease and Cancer

Immunology and Cell Biology
AllergyImmunologyCell Biology
2020English

Physicochemical and Functional Characterization of a Biosimilar Adalimumab ZRC-3197

Biosimilars
2014English

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

BioDrugs
MedicineBiotechnologyPharmacology
2016English

OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis

2017English

Functional Analysis of the Anti-Adalimumab Response Using Patient-Derived Monoclonal Antibodies

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2014English

Safety of Adalimumab Biosimilar MSB11022 (Acetate-Buffered Formulation) in Patients With Moderately-To-Severely Active Rheumatoid Arthritis

Clinical Rheumatology
MedicineRheumatology
2019English

A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501

Advances in Therapy
MedicinePharmacology
2019English

Revisiting Field Capacity (FC): Variation of Definition of FC and Its Estimation From Pedotransfer Functions

Revista Brasileira de Ciencia do Solo
AgronomySoil ScienceCrop Science
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy